Gout, Hyperuricemia
Conditions
Brief summary
This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of \[14C\] radiolabeled LC350189 after oral administration.
Interventions
DRUG[14C] LC350189
Carbon-14 labelded LC350189
Sponsors
LG Chem
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* The subject is male 18 to 55 years of age, inclusive. * The subject has a body mass index 18 to 32 kg/m2, inclusive, at screening. * The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead electrocardiogram results, and physical examination findings at screening. * The subject is able to provide written informed consent.
Exclusion criteria
* The subject has a medical history of any issues affecting absorption or metabolism, as judged by the investigator. * The subject has a medical history of any problems affecting venous access or bowel/bladder function. * The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening. * The subject has used any prescription or over the counter medications (except paracetamol \[up to 2 g per day\]), including herbal or nutritional supplements, within 14 days before the first dose of study drug. * The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange containing products (eg, marmalade), or caffeine- or xanthine containing products within 48 hours before the first dose of study drug or during the study. * The subject has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or before the first dose of study drug. * The subject is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug or during the study. * The subject has donated blood or blood products \>450 mL within 30 days before the first dose of study drug. * The subject has a history of relevant drug and/or food allergies (ie, allergy to study drug or excipients, or any significant food allergy that could preclude a standard diet in the clinical unit).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mass balance recovery of total radioactivity in whole blood and plasma. | Before dosing on Days 1 through Day 10 (240 hours) | Radioactivity is measured by radiation dosimetry. |
| Mass balance recovery of total radioactivity in whole urine, and feces. | Before dosing on Days 1 through Day 10 (240 hours) | Radioactivity is measured by radiation dosimetry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | form baseline up to Day 11 | Safety |
Countries
United States
Outcome results
None listed